Shelly Folsom

Shelly Folsom has extensive work experience in drug safety operations. Shelly currently holds the position of Director of Drug Safety Operations at Nuvation Bio, starting in October 2021. Prior to that, they worked at Kartos Therapeutics, Inc. as Director of Drug Safety Operations from March 2020 to October 2021. Shelly also had a director-level role at FibroGen, Inc. as Director of Drug Safety Operations from January 2019 to March 2020, and as Associate Director from February 2017 to January 2019. Additionally, they held the position of Senior Clinical Safety Manager at Rigel Pharmaceuticals Inc. from September 2015 to February 2017. Before that, they worked in various roles at Onyx Pharmaceuticals, Talon Therapeutics, Jazz Pharmaceuticals, Gilead Sciences, Alta Bates Medical Center, and Aerogen in the fields of medical safety review, drug safety, and clinical safety management. Shelly's extensive work experience showcases their expertise and leadership in drug safety operations.

Shelly Folsom obtained a Bachelor's degree in Biology from UC San Diego in 1996. Following this, they pursued a Master's degree in Nursing from Samuel Merritt University, which they completed in 2002.